Articles tagged with Angiotensin Converting Enzyme 2
Researchers analyzed protein sequences to understand how SARS-CoV-2 infects cells, identifying short linear motifs involved in endocytosis and autophagy. The findings suggest potential new therapeutic approaches for COVID-19, including the use of existing drugs that interfere with these cellular processes.
A new protein has been developed that acts as a decoy to prevent the COVID-19 infection from entering human cells. The protein is a modified variant of ACE2, which intercepts the S spike of the coronavirus and fools it into binding to it rather than the real receptor.
The N439K mutation in the SARS-CoV-2 Spike protein confers resistance to serum antibodies and monoclonal antibodies, including those used in treatments. Researchers found that viruses with this mutation bind more strongly to the human ACE2 receptor, evading immunity while retaining infectivity.
Researchers have identified a promising therapeutic combination for renal cell carcinoma, utilizing ACE2 expression analysis. The study found that higher ACE2 expression correlates with better overall survival in patients with RCC.
Researchers discovered a new, shorter form of ACE2 that lacks the viral binding site, contradicting previous studies. This finding supports the use of interferon-based treatments for COVID-19 patients.
A UCLA-led study uses 3D-printed models to identify possible link between COVID-19 and stroke. The researchers found that the coronavirus increases the production of a molecule called angiotensin-converting enzyme 2 (ACE2), which affects blood vessel cells in the brain.
A recent study found that female COVID-19 patients experience less severe complications due to stronger immune responses triggered by their X chromosome-linked genes. Women's immune systems are enhanced by the presence of Toll-like receptor seven, allowing them to better tolerate virus infections.
Researchers from Cleveland Clinic note that COVID-19 can affect the central nervous system, causing disorders such as ischemic stroke, encephalitis, and epileptic seizures. The virus enters the brain through the blood-brain barrier or nasal cavity, triggering a cytokine storm that leads to inflammation and damage.
Penn State researchers computationally modeled the attachment of SARS-CoV-2 protein spike to ACE2, finding it highly optimized for human binding. The team also explored changes in the virus spike that could alter its affinity with human ACE2, potentially informing future research on vaccine durability and animal transmission.
A new study from Cedars-Sinai found that the ACE2 enzyme, which helps coronavirus infect cells, also plays a role in gut inflammation and patient outcomes in inflammatory bowel disease. Treatment with anti-inflammatory drugs for IBD may aid recovery from COVID-19.
Researchers developed a synthetic mini-antibody called sybody 23 that can block SARS-CoV-2's ability to infect human cells. This breakthrough could lead to a potential way to treat COVID-19, with further analyses planned to confirm its effectiveness.
SARS-CoV-2 spike proteins can cause inflammation on endothelial cells forming the blood-brain barrier, making it 'leaky' and disrupting neural networks. This could lead to neuroinvasion and neurological manifestations in COVID-19 patients, especially those with pre-existing health conditions.
This study identifies potential anti-COVID-19 pharmacological components of TCM's Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening. The research demonstrates the utility of this approach for identifying pharmaceutically active components in Chinese herb medicines.
Researchers found that CBD increases apelin levels, which reduces inflammation and improves oxygen levels in the lungs. CBD treatment also normalized lung function and reduced physical damage caused by ARDS.
Researchers identify glycans linked to the SARS-CoV-2 spike protein as key players in infection, stabilizing shape change that exposes receptor-binding domain. Mutations reducing glycanaction can reduce binding to ACE2.
Researchers developed SARS-CoV-2 nanoparticle probes to track host cell surface Angiotensin Converting Enzyme 2 (ACE2) binding and endocytosis. These non-infectious probes enable real-time tracking of viral attachment and effects on cells, offering a powerful system for studying COVID-19 mechanisms.
Researchers at the Francis Crick Institute have characterized ten distinct structures of the SARS-CoV-2 spike protein and its interaction with human cells. The study provides new insight into the virus's ability to infect human cells and informs the development of vaccines and treatments.
Researchers at Sechenov University study immune reactions to develop an effective vaccine against SARS-CoV-2. The key finding is that vaccines should induce high-affinity neutralizing antibodies targeting ACE2, while avoiding eosinophilic complications.
A study by researchers at the University of Rochester Medical Center found that vaping and smoking are linked to an increased risk of COVID-19 in young people. The research team is investigating the role of ACE2 receptors in this connection, which may help identify vulnerable individuals who can be better monitored.
A new LSU Health study reveals that the angiotensin-converting enzyme 2 (ACE2) receptor plays a crucial role in the multipronged SARS-CoV-2 attack, leading to widespread COVID-19 infection. The research found high ACE2 expression in various organs and tissues, including the respiratory, digestive, and reproductive systems.
Researchers developed a lethal mouse model for SARS-CoV-2 by infecting genetically engineered K18-hACE2 mice with the virus. The study reveals acute disease symptoms and fatal outcomes in these mice, providing a valuable platform for medical countermeasure development.
A review of preclinical data suggests estrogen lowers ACE2 levels, which may explain why women experience milder symptoms. Higher ACE2 levels in men could account for worse outcomes.
A recent study using genomic analysis compared the ACE2 protein in over 410 species and found that many animals with all 25 amino acid residues matching the human protein are at high risk for contracting SARS-CoV-2 via ACE2. This includes critically endangered primate species, marine mammals, and certain domestic animals.
Researchers found high levels of ACE2 receptors in sustentacular cells lining the nose, which may be a key entry point for SARS-CoV-2. This discovery could lead to targeted therapies and help explain why some people with COVID-19 lose their sense of smell.
Researchers designed a novel receptor that binds to the SARS-CoV-2 virus, preventing it from entering cells. The decoy receptor has potent neutralizing activity against SARS-CoV-2 and also acts against SARS-CoV-1, a closely related virus.
A team of researchers at McMaster University has discovered that the ACE2 receptor is present in very low levels in human lung tissue, suggesting alternative infection pathways. This finding challenges existing knowledge about SARS-CoV-2 entry into cells and may lead to better diagnostic devices and treatment strategies.
Researchers at UC Davis aim to create humanized mice by replacing mouse ACE2 with human ACE2 using CRISPR-Cas9 technology, allowing for the study of COVID-19 disease progression and susceptibility variations.
A recent study published in ACS Pharmacology & Translational Science found that COVID-19 does not directly damage taste bud cells, contradicting previous studies. Instead, the researchers suggest that taste loss is likely caused by events induced during COVID-19 inflammation.
Researchers at Uppsala University have discovered that the ACE2 enzyme is present throughout the human body, but at very low levels in the respiratory system. This finding suggests that other factors may be necessary for SARS-CoV-2 infection and disease progression.
Research in mice indicates ACE2 receptor is primarily found on tongue cells with rough surfaces, not in taste bud cells, suggesting alternative mechanisms for SARS-CoV-2-induced taste loss.
Researchers identified a promising soluble variant of the human receptor for SARS-CoV-2 that competes with monoclonal antibodies. The variant, dubbed sACE2.v2.4, neutralizes both SARS-CoV-2 and SARS-CoV-1 in cell-based assays.
A team of scientists has engineered a decoy receptor protein that binds to the SARS-CoV-2 virus and blocks infection in human cells. The research found that this decoy receptor is attractive to the virus due to subtle mutations, making it an ideal candidate for neutralizing the virus.
Researchers found that certain microRNAs can decrease the expression of ACE2 and TMPRSS2 enzymes, which are crucial for SARS-CoV-2 entry into human cells. This discovery could lead to new approaches for fighting the virus.
A new Northwestern University study in mice found ACE inhibitors and angiotensin receptor blockers do not increase COVID-19 severity or fatality risk. The research dispels concerns about these widely used drugs in patients with hypertension and cardiovascular disease.
A new diagnostic test for heart failure patients has been found to also predict COVID-19 patient outcomes, highlighting the connection between cardiovascular disease and COVID-19. The test measures a balance of beneficial and harmful peptides in the blood, suggesting that targeting this pathway could improve treatment for both conditions.
A recent Cleveland Clinic study has identified genetic factors that may influence an individual's susceptibility to COVID-19. The research found associations between polymorphisms in the ACE2 and TMPRSS2 genes and increased risk of cardiovascular and pulmonary conditions, as well as poor outcomes with COVID-19.
Several newly discovered human antibodies target the SARS-CoV-2 virus, offering promising therapeutic leads and potential protection against new coronavirus outbreaks. Researchers have isolated hundreds of antibodies from convalescent donors, with some showing strong cross-neutralization capabilities against related bat coronaviruses.
Researchers developed a COVID-19 mouse model that replicates the illness in people, allowing for accelerated testing of experimental treatments and vaccines. The model can also study risk factors for severe illness, such as obesity and advanced age.
Mount Sinai researchers found lower ACE2 expression in younger children, increasing with age. This could help explain why children are less likely to get COVID-19 and account for only 2% of identified cases.
Researchers are studying COVID-19's effects on the brain, including stroke, anosmia, and seizures. They hope to find better treatments for patients at risk of developing cognitive problems.
Researchers report increased ACE2 expression in smokers' lungs, possibly resulting in COVID-19 morbidity. Smoking causes a significant increase in the protein's production, tied to goblet cell hyperplasia and associated with COPD and idiopathic pulmonary fibrosis.
Research suggests that cigarette smoke triggers an increase in ACE2 receptors in the lungs, a protein used by the coronavirus to enter human cells. Quitting smoking may reduce this risk.
A large study found that men have higher concentrations of ACE2 in their blood, which enables the coronavirus to infect healthy cells. This may explain why men with heart failure are more susceptible to COVID-19 than women. The study also found no link between RAAS inhibitors and increased ACE2 concentrations.
A NIH-funded study aims to measure the rate of novel coronavirus infection in US children and their family members, as well as the percentage of infected children who develop COVID-19. The study also explores whether asthma or other allergic conditions affect SARS-CoV-2 infection rates.
Russian scientists have developed a new line of humanized mice sensitive to SARS-CoV-2, allowing for the testing of COVID-19 vaccines and drugs. The mice are made biologically safe and can experience symptoms and pathogenesis similar to humans, reducing the risk of contagion in laboratories.
A study of 12,594 patients found that common high blood pressure drugs did not increase the risk of contracting or developing severe COVID-19. The research suggests that these medications can be safely used in patients with COVID-19 disease.
Researchers at Mayo Clinic have discovered a potential link between heart disease and worse COVID-19 outcomes. The study found that patients with obstructive hypertrophic cardiomyopathy had elevated levels of the ACE2 protein, which the SARS-CoV-2 virus uses to gain entry into cells.
Goblet cells in nasal passages highly express ACE2 receptor, allowing COVID-19 virus to enter airway cells. Researchers suggest these cells may serve as viral reservoir, helping to disseminate the disease.
A new study reveals that only a small percentage of respiratory and intestinal cells express the necessary receptors, making them susceptible to SARS-CoV-2 infection. Interestingly, the virus may exploit one of the body's main defenses, interferon, to gain entry into these cells.
Researchers at Karolinska Institutet and UBC found that a genetically modified variant of ACE2 reduced SARS-CoV-2 viral growth by a factor of 1,000 to 5,000 in cell cultures. The study suggests the potential for a novel drug treatment to help patients with early-stage COVID-19.
A new trial drug, APN01, has been found to effectively block the SARS-CoV-2 virus from infecting its hosts, holding promise as a treatment for COVID-19. The study provides valuable insights into the key aspects of the novel coronavirus and its interactions with cells.
ACE inhibitors and ARBs may raise the risk of severe COVID-19 outcomes due to increased ACE2 receptors in the lungs. Patients with hypertension, coronary artery disease, diabetes, and chronic renal disease are more susceptible.
Scientists have created a protein drug composed of angiotensin converting enzyme-2 (ACE2) and its product angiotensin (1-7) that can be taken orally to treat pulmonary arterial hypertension. The drug has shown promise in animal models, reducing pulmonary artery pressure and improving cardiac function.
Scientists analyze Wuhan CoV genetic relationship with other coronaviruses and model its spike protein to evaluate human transmission risk. The study suggests bats as the native host of Wuhan CoV, but intermediate hosts may be involved in transmission.
Researchers found similarities between the novel Wuhan coronavirus's receptors and those of SARS-CoV, a key finding in understanding its ability to infect humans. The study suggests that mutations in the virus could enhance its binding to human ACE2, leading to increased transmission.
Researchers discovered using plants to produce an enzyme may improve treatment for life-threatening lung high blood pressure. The study found that replenishing ACE2 protein helped decrease pulmonary blood pressure and increase pulmonary blood flow in rats.
A study found that ACE2 is protective against diabetic complications in both lab models and human patients. High levels of ACE2 in vascular reparative cells prevent heart function decline and renal failure in diabetics.
A new therapeutic approach to treating hypertension may be possible using an enzyme called ACE2, which breaks down angiotensin II in the system. This approach could provide a more complete and effective suppression of the renin-angiotensin system, treating not just hypertension but also other medical conditions.
The Canadian Cardiovascular Society recognizes Dr. Gavin Y. Oudit's groundbreaking research on a new class of drugs for treating heart failure, with the potential to also treat kidney and lung diseases. Oudit's innovative program has yielded major discoveries and established him as a world leader in this exciting area of research.
Researchers at Louisiana State University Health Sciences Center have found a potential new target for hypertension treatment in the brain's Angiotensin-converting enzyme 2 (ACE2). By blocking one of its receptors, AT1Rs, ACE2 activity increased, normalizing impaired baroreceptor reflex function and blood pressure.